The FDA said it has received postmarketing reports of neutralizing antibodies to ADAMTS13, including one death, in patients ...

The U.S. Food and Drug Administration said on Friday it is investigating the death of a child who developed harmful ...

The ACR issued a 2025 guideline for the treatment of SLE that addressed treatment and management of specific organ system ...

The regulator has received reports that a group of patients treated with Adzynma had neutralizing antibodies against the ...

EULAR - The European Alliance of Associations for Rheumatology - has developed a new disease activity score that quantifies ...

NANJING -- A Chinese research team has developed a combination of nanobodies that shows potent and broad efficacy against ...

Researchers from the Second Affiliated Hospital of Nanjing Medical University, et al. have published a case report entitled ...

Takeda Pharmaceutical (TAK) stock is in focus as the company's blood disease drug Adzynma is linked to a patient death, ...

The European Alliance of Associations for Rheumatology – has developed a new disease activity score that quantifies the level of disease activity in people with antiphospholipid syndrome (APS). It ...

Takeda Pharmaceuticals' drug Adzynma is being investigated by the U.S. Food and Drug Administration due to a death following treatment. The FDA said Friday it has received reports of neutralizing ...

The FDA has opened an investigation into Takeda’s recombinant protein med Adzynma following the reported death of a pediatric patient who received the drug. | The FDA has opened an investigation into ...

Since approval, the Food and Drug Administration has received postmarketing reports of neutralizing antibodies to ADAMTS13, including one death, in congenital thrombotic thrombocytopenic purpura ...